The platelet function defect of paroxysmal nocturnal haemoglobinuria

Platelets

Volumn 15, Issue 3, 2004, Pages 145-154

  Grünewald, Martin ^a   Grünewald, Anja ^a   Schmid, Anke ^a   Schöpflin, Christine ^a   Schauer, Stefanie ^a   Griesshammer, Martin ^a   Koksch, Mario ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CD63 ANTIGEN; DECAY ACCELERATING FACTOR; GLYPICAN; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOSPONDIN;

ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CELL CLONE; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DEVICE; DOWN REGULATION; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HEMOGLOBIN DETERMINATION; HEMOGLOBINURIA; HUMAN; HUMAN CELL; INTRAVASCULAR HEMOLYSIS; LEUKOCYTE COUNT; LIFESPAN; LIGAND BINDING; MALE; MONOCYTE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETICULOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOPHENOTYPING; MEMBRANE PROTEINS; MIDDLE AGED; PANCYTOPENIA; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; RECEPTORS, CELL SURFACE;

EID: 2442575712     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537105310001657110     Document Type: Article

References (54)

1. Hillmen P, Richards S J. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 108: 470-9.
2. Hall C, Richards S J, Hillmen P. The glycosylphosphatidyl-inositol anchor and paroxysmal nocturnal haemoglobinuria/aplasia model. Acta Haematol 2002; 108: 219-30.
3. Rotoli B, Bessler M, Alfinito F, Del Vecchio L. Membrane proteins in paroxysmal nocturnal haemoglobinuria. Blood Rev 1993; 7: 75-86.
4. Yeh E T H, Rosse W F. Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol anchor. J Clin Invest 1994; 93: 2305-10.
5. Hillmen P, Lewis S M, Bessler M, Luzzatto L, Dacie J V. Natural history of paroxysmal nocturnal hemoglobinuria. New Engl J Med 1995; 333: 1253-8.
6. Schrezenmeier H, Hildebrand A, Rojewski M, Häcker H, Heimpel H, Raghavachar A. Paroxysmal nocturnal haemoglobinuria: a replacement of haemopoietic tissue? Acta Haematol 2000; 103: 41-8.
7. Nishimura J, Phillips K L, Ware R E, Hall S, Wilson L, Gentry T L, et al. Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype. Blood 2001; 97: 3004-10.
8. Bessler M, Mason P J, Hillmen P, Miyata T, Yamada N, Takeda J, et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994; 13: 110-7.
9. Socié G, Mary J, De Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet 1996; 348: 573-7.
10. Ray J G, Burows R F, Ginsberg J S, Burrows E A. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis 2000; 30: 103-17.
11. Tudela M, Jarque I, Perez-Sirvent M L, Palau J, Sanz M A. Clinical profile and course of paroxysmal nocturnal hemoglobinuria. Sangre (Barcelona) 1993; 38: 301-7.
12. Bais J, Pel M, Von dem Borne A, Van der Lelie H. Pregnancy and paroxysmal nocturnal hemoglobinuria. Eur J Obstet Gynecol Reprod Biol 1994; 53: 211-4.
13. Mathieu D, Rahmouni A, Villeneuve P, Anglade M C, Rochant H, Vasile N. Impact of magnetic resonance imaging on the diagnosis of abdominal complications of paroxysmal nocturnal hemoglobinuria. Blood 1995; 85: 3283-8.
14. Ploug M, Plesner T, Ronne E, Ellis V, Hoyer-Hansen G, Hansen N E, et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 1992; 79: 1447-55.
15. Grünewald M, Siegemund A, Grünewald A, Schmid A, Koksch M, Schöpflin C, et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. Blood Coagul Fibrinolysis 2003; 14: 685-95.
16. Ronne E, Pappot H, Grondahl-Hansen J, Hoyer-Hansen G, Plesner T, Hansen N E, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 89: 576-81.
17. Ninomiya H, Hasegawa Y, Nagasawa T, Abe T. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity. Int J Hematol 1997; 65: 285-91.
18. Gao W, Wang Z, Bai X, Li Y, Ruan C. Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria. Int J Hematol 2002; 75: 434-9.
19. Takahashi H, Izumi T, Toshima M, Kawano C, Komatsu N, Imagaua S, et al. Thrombotic complication in the course of aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome; possible involvement of dysplasminogenemia (plasminogen Tochigi) in the pathogenesis of thrombosis. Rinsho Ketsueki 1996; 37: 249-54.
20. Gralnick H R, Vail M, McKeown L P, Merryman P, Wilson O, Chu I, et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 91: 697-702.
21. Sims P J, Faioni E M, Wiedmer T, Shattil S J. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-12.
22. Wiedmer T, Hall S E, Ortel T L, Kane W H, Rosse W F, Sims P J. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993; 82: 1192-6.
23. Hugel B, Socié G, Vu T, Toti F, Gluckman E, Freyssinet J M, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 3451-6.
24. Oelschlaegel U, Besson I, Arnoulet C, Sainty D, Nowak R, Naumann R. et al. A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes. Clin Lab Haematol 2001; 23: 81-90.
25. Hernandez-Campo P M, Martin-Ayuso M, Almeida J, Lopez A, Orfao A. Comparative analysis of different flow cytometry-based immunophenotypic methods for the analysis of CD59 and CD55 expression on major peripheral blood cell subsets. Cytometry 2002; 50: 191-201.
26. Piedras J, Lopez-Karpovitch X. Flow cytometric analysis of glycosylphosphatidyl-inositol-anchored proteins to assess paroxysmal nocturnal hemoglobinuria clone size. Cytometry 2000; 42: 234-8.
27. Hartert H. Blutgerinnungsstudien mit der Thrombelastographie. Klin Wochenschr 1948; 26: 577-82.
28. Mallett S V, Cox D J A. Thrombelastography. Br J Anesthesia 1992; 69: 307-13.
29. Kratzer M A A, Born G V R. Simulation of primary hemostasis in vitro. Haemostasis 1985; 15: 357-62.
30. Kratzer M A A, Bellucci S, Caen J P. Detection of abnormal platelet function with an in vitro model of primary hemostasis. Haemostasis 1985; 15: 363-70.
31. Hellem A J. Platelet adhesiveness in von Willebrand's disease. A study with a new modification of the glass bead filter method. Scand J Haematol 1970; 7: 374-82.
32. Born G V R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
33. Ginsberg M H, Frelinger A L, Lam S C-T, Forsyth J, McMillan R, Plow E F, et al. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood 1990; 76: 2017-23.
34. Johnson R J, Hillmen P. Paroxysmal nocturnal haemoglobinuria: nature's gene therapy? Mol Pathol 2002; 55: 145-52.
35. Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson K J, et al. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-96.
36. Mammen E F. Ten years' experience with the 'sticky platelet syndrome'. Clin Appl Thromb Hemost 1995; 1: 66-72.
37. Shattil S J, Cunningham M, Hoxie J A. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-15.
38. Tschoepe D, Spangenberg P, Esser J, Schwippert B, Kehrel B, Roesen P, et al. Flow-cytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actin status of activated platelets. Cytometry 1990; 11: 652-6.
39. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis H K, Kehrel B, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17: 433-8.
40. Scharf R E, Tomer A, Marzec U M, Teirstein P S, Ruggeri Z M, Harker L A. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 1992; 12: 1475-87.
41. Kannan K, Divers S G, Lurie A A, Chervenak R, Fukuda M, Holcombe R F. Cell surface expression of lysosome-associated membrane protein-2 (lamp2) and CD63 as markers of in vivo platelet activation in malignancy. Eur J Haematol 1995; 55: 145-51.
42. Furman M I, Benoit S E, Barnard M R, Valeri C R, Borbone M L, Becker R C, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Clin Cardiol 1998; 31: 352-8.
43. Zeller J A, Tschoepe D, Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 1999; 81: 373-7.
44. Griesshammer M, Beneke H, Nussbaumer B, Grünewald M, Bangerter M, Bergmann L. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res 1999; 96: 191-6.
45. Joseph J E, Harrison P, Mackie I J, Isenberg D A, Machin S J. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115: 451-9.
46. Koksch M, Zeiger F, Wittig K, Siegemund A, Reininger C B, Pfeiffer D, et al. Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease. Eur J Vasc Endovasc Surg 2001; 21: 147-54.
47. Carter A M, Catto A J, Bamford J M, Grant P J. Platelet GP IIIa P1A and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol 1998; 18: 1124-31.
48. Carter A M, Catto A J, Bamford J M, Grant P J. Association of the platelet glycoprotein IIb HPA-3 polymorphism with survival after acute ischemic stroke. Stroke 1999; 30: 2606-11.
49. Nurden A T. Inherited abnormalities of platelets. Thromb Haemost 1999; 82: 468-80.
50. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1: 1628-36.
51. Seyfarth H J, Koksch M, Roethig G, Rother T, Neugebauer A, Klein N, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002; 143: 118-23.
52. Catimel B, Parmentier S, Leung L L, McGregor J L. Separation of important new platelet glycoproteins (GPIa, GPIc, GPIc*, GPIIa and GMP-140) by f.p.l.c. Characterization by monoclonal antibodies and gas-phase sequencing. Biochem J 1991; 279: 419-25.
53. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003; 102: 3587-91.
54. Rosenberg R D, Aird W C. Vascular-bed-specific hemostasis and hypercoagulable states. New Engl J Med 1999; 340: 1555-64.